ABBV vs DELL: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Dell Technologies Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-10.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Dell Technologies Inc. · Technology
$450.22
-13.0% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
DELL trades at a lower forward P/E
(35.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
DELL |
| Current Price |
$261.07 |
$450.22 |
| Fair Value Estimate |
$264.30 |
$391.48 |
| Upside to Fair Value |
+1.2%
|
-13.0%
|
| Market Cap |
$461.3B |
$299.1B |
| Forward P/E |
128.0x
|
35.2x
|
| EV / EBITDA |
31.0x
|
22.9x
|
| Price / Sales |
7.3x
|
2.2x
|
| Price / FCF |
22.1x
|
31.7x
|
| Revenue Growth YoY |
+12.4%
|
+87.5%
|
| Gross Margin |
70.7%
|
19.2%
|
| Operating Margin |
27.6%
|
8.0%
|
| Return on Equity |
68.0%
|
-363.2%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
3.16%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Dell Technologies Inc. operates in the technology sector focusing on computer hardware, delivering strong revenue and earnings growth in the most recent quarter with 87.5% and 256.3% year-over-year increases respectively. Despite these impressive growth metrics and a solid operating margin of 8.0%, the company is currently overvalued with its stock trading 13% above the fair value estimate of $39…
Accumulation Zones
| Metric |
ABBV |
DELL |
| Zone Low |
$198.23 |
$293.61 |
| Zone High |
$224.66 |
$332.76 |
| In Buy Zone? |
No
|
No
|